Company: Omega Therapeutics
Job title: President and CEO
Mahesh Karande is President and CEO of Omega Therapeutics, a genomic medicines company, based in Cambridge, Massachusetts. Mr. Karande is a patient-centric, geo-diverse, people and results-oriented chief executive with early-stage biotech, significant P&L and large team/country leadership experiences. He has strong operational and business-building experiences combined with a global work history spanning the U.S., Europe, Asia and Africa.
He is deeply experienced in running biopharma businesses across discovery, preclinical development, clinical development, commercialization and product lifecycle management stages. His breadth of therapeutic experiences span gene-based therapies, oncology, general medicines (specialty and primary care), critical/acute care, antibiotics, hospital products, and medical devices. He has been involved with 10+ product launches in the U.S. and across global markets.
Most recently, Mr. Karande was president and CEO of Macrolide Pharmaceuticals. Earlier, Mr. Karande spent several years at Novartis, leading various U.S. and international business units. Mr. Karande has an M.B.A. from the Wharton School, University of Pennsylvania. He is also a graduate of the Georgia Institute of Technology where he completed his M.S. in engineering and the University of Bombay where he completed undergraduate studies in engineering.
Panel: The Role of Epigenetics in an Oncology Portfolio 5:40 pm
Utilizing epigenetics in combination with immunotherapies to further bolster the immune response Building a differentiated oncology portfolio based on standalone epigenetic (mono)therapies Imagining the future of epigenetic therapies in oncology and beyondRead more
day: Virtual Conference Day